Retatrutide
New Clients
Starting at $380 / month
Retatrutide is a groundbreaking triple agonist that targets glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1, synergistically enhancing insulin secretion, improving glucose homeostasis, and refining appetite modulation. individuals on retatrutide lost 22% of body weight at 48-weeks of treatment.
beyond glycemic control and weight reduction, retatrutide shows promise in mitigating cardiovascular risk factors and addressing non-alcoholic fatty liver disease, expanding its potential impact on metabolic health.
FSA & HSA payments accepted
All services provided have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. The material on this website is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any treatment or therapy program. Any designations or references to therapies are for marketing purposes only and do not represent actual products.